BI 54903 XX

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Healthy

Phase 1

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

CompletedNCT02220660

Boehringer IngelheimHealthy

Start: 2009-03-31Updated: 2014-08-20

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

CompletedNCT02222428

Boehringer IngelheimHealthy

Start: 2009-04-30Target: 36Updated: 2014-08-21